Flaig TW - Search Results

1

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. O'Donnell PH, et al. Among authors: flaig tw. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369081 Free PMC article. Clinical Trial.

2

Multifunctional nanoclusters of NaYF₄:Yb³⁺,Er³⁺ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer.

Cho SK, Su LJ, Mao C, Wolenski CD, Flaig TW, Park W. Cho SK, et al. Among authors: flaig tw. Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:784-792. doi: 10.1016/j.msec.2018.12.113. Epub 2018 Dec 29. Mater Sci Eng C Mater Biol Appl. 2019. PMID: 30678969 Free PMC article.

3

Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database.

Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Amini A, et al. Among authors: flaig tw. Urol Oncol. 2017 Jun;35(6):438-446. doi: 10.1016/j.urolonc.2017.01.013. Epub 2017 Feb 15. Urol Oncol. 2017. PMID: 28214281

4

A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma?

Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S. Flaig TW, et al. Oncology (Williston Park). 2009 Feb;23(2):177-80. Oncology (Williston Park). 2009. PMID: 19323300 Free article. No abstract available.

5

The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma.

Bourlon MT, Flaig TW. Bourlon MT, et al. Among authors: flaig tw. Curr Drug Targets. 2016;17(2):196-205. doi: 10.2174/1389450116666150213120731. Curr Drug Targets. 2016. PMID: 26044568 Review.

6

Visceral metastases in prostate cancer: an underestimated and understudied subgroup.

Bourlon MT, Flaig TW. Bourlon MT, et al. Among authors: flaig tw. Oncology (Williston Park). 2014 Nov;28(11):980-6. Oncology (Williston Park). 2014. PMID: 25403630 Free article. No abstract available.

7

Management of the side effects of androgen deprivation therapy in men with prostate cancer.

Flaig TW, Glodé LM. Flaig TW, et al. Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. doi: 10.1517/14656566.9.16.2829. Expert Opin Pharmacother. 2008. PMID: 18937615 Review.

8

The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model.

Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. Yang X, et al. Among authors: flaig tw. Bladder Cancer. 2017 Jul 27;3(3):201-210. doi: 10.3233/BLC-170096. Bladder Cancer. 2017. PMID: 28824948 Free PMC article.

9

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Flaig TW, et al. BJU Int. 2009 Jun;103(12):1729-37. doi: 10.1111/j.1464-410X.2009.08367.x. Epub 2009 Feb 10. BJU Int. 2009. PMID: 19220256

10

Silibinin suppresses CD44 expression in prostate cancer cells.

Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Handorean AM, et al. Among authors: flaig tw. Am J Transl Res. 2009 Jan 1;1(1):80-6. Am J Transl Res. 2009. PMID: 19966941 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

154 results

Search Page